KRAS and non-small cell lung carcinoma: Besides in PDAC [38, 68] some progress has already been achieved with these molecules in several treatment-resistant forms of cancer, including KRAS-mutant and TKI-resistant non-small cell lung cancer [37, 70], castration-resistant prostate cancer [71], endometrial cancer [72], leukemia [38, 73–75] and neuroblastoma [76].